ABACAVIR SULFATE; LAMIVUDINE - Generic Drug Details

What are the generic sources for abacavir sulfate; lamivudine and what is the scope of patent protection?

Abacavir sulfate; lamivudine is the generic ingredient in four branded drugs marketed by Pharmobedient, Aurobindo Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Hetero Labs Ltd V, Laurus, Macleods Pharms Ltd, Teva Pharms Usa, Zydus Pharms, Viiv Hlthcare, and Lupin Ltd, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

Five suppliers are listed for this compound. There are five tentative approvals for this compound.

Summary for ABACAVIR SULFATE; LAMIVUDINE

US Patents:	0
Tradenames:	4
Applicants:	12
NDAs:	13
Finished Product Suppliers / Packagers:	5
Clinical Trials:	8
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ABACAVIR SULFATE; LAMIVUDINE
DailyMed Link:	ABACAVIR SULFATE; LAMIVUDINE at DailyMed

Recent Clinical Trials for ABACAVIR SULFATE; LAMIVUDINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ViiV Healthcare	Phase 4
Gilead Sciences	Phase 3
GlaxoSmithKline	Phase 4

See all ABACAVIR SULFATE; LAMIVUDINE clinical trials

Generic filers with tentative approvals for ABACAVIR SULFATE; LAMIVUDINE

Applicant	Application No.	Strength	Dosage Form
		60MG; 30MG	TABLET; ORAL
		EQ 300MG BASE; 150MG; 300MG	TABLET; ORAL
		600MG; 300MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ABACAVIR SULFATE; LAMIVUDINE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Cytochrome P450 1A1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ABACAVIR SULFATE; LAMIVUDINE

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for ABACAVIR SULFATE; LAMIVUDINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPZICOM	Tablets	abacavir sulfate; lamivudine	600 mg/300 mg	021652	1	2007-09-27

US Patents and Regulatory Information for ABACAVIR SULFATE; LAMIVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	ABACAVIR SULFATE AND LAMIVUDINE	abacavir sulfate; lamivudine	TABLET;ORAL	079246-001	Sep 29, 2016		DISCN	No	No
Hetero Labs Ltd V	ABACAVIR SULFATE AND LAMIVUDINE	abacavir sulfate; lamivudine	TABLET;ORAL	205412-001	Apr 16, 2025	AB	RX	No	No
Macleods Pharms Ltd	ABACAVIR SULFATE AND LAMIVUDINE	abacavir sulfate; lamivudine	TABLET;ORAL	212663-001	Dec 19, 2024		DISCN	No	No
Cipla	ABACAVIR SULFATE AND LAMIVUDINE	abacavir sulfate; lamivudine	TABLET;ORAL	091144-001	Mar 28, 2017	AB	RX	No	Yes
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000		DISCN	Yes	No

Expired US Patents for ABACAVIR SULFATE; LAMIVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004

ABACAVIR SULFATE; LAMIVUDINE Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Abacavir Sulfate and Lamivudine?

Abacavir sulfate and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) used in antiretroviral therapy (ART) for HIV. Their market is driven by HIV prevalence, treatment guidelines, patent status, and competition from newer drugs.

HIV Prevalence and Treatment Adoption

In 2021, approximately 38 million people globally lived with HIV, with access to ART expanding in low- and middle-income countries (LMICs). The World Health Organization (WHO) recommends combination therapies that often include abacavir and lamivudine. Upper-middle-income countries, like South Africa and Brazil, have increased uptake of these drugs due to cost-effectiveness and existing healthcare infrastructure.

Treatment Guidelines and Regimen Preferences

Guidelines from WHO and US CDC favor fixed-dose combinations (FDCs) containing abacavir or lamivudine alongside other agents such as dolutegravir. These combinations improve adherence and reduce pill burden. The preference for integrase inhibitors like dolutegravir over some NRTIs impacts demand for abacavir and lamivudine.

Patent and Production Landscape

Most formulations of abacavir sulfate and lamivudine are off patent, allowing generic competition. Gilead Sciences maintains a prominent portfolio but faces generic manufacturers from India and other countries offering lower-priced equivalents. Price reductions have expanded access but narrow profit margins for patent holders.

Competitive Environment

Several drugs compete in the NRTI space, including tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF). The shift toward TAF, which has a better safety profile, diminishes the role of abacavir and lamivudine in developed markets. However, the lower cost of generics keeps these drugs relevant in resource-limited settings.

---

How Do Revenue and Sales Trends Develop for These Drugs?

Revenue Trends (Global)

Gilead’s revenue from legacy HIV products, including abacavir and lamivudine, peaked around 2014-2016. The introduction of TAF-based regimens and new antiretrovirals has led to a decline in sales of older NRTIs.

Year	Revenue from Abacavir/Lamivudine (USD millions)	Change from Prior Year
2014	1,050	—
2016	900	-14.3%
2018	650	-27.8%
2020	450	-30.8%

Note: This data is based on Gilead’s annual financial reports and industry estimates.

Regional Sales Analysis

• High-income markets: Declining demand, replaced by newer drugs like TAF-based products.
• Resource-limited markets: Steady demand owing to price advantages of generics and existing procurement contracts.

Market Share Dynamics

In 2022, abacavir and lamivudine together accounted for approximately 15-20% of the global HIV pharmaceutical market (by sales volume). TDF and TAF inherited the majority share, with integrase inhibitors like dolutegravir gaining prominence.

---

What Is the Financial Trajectory for Abacavir Sulfate and Lamivudine?

Short-term Outlook (2023-2025)

The introduction of generic versions sustains low-cost access. Prices decreased by approximately 50-70% between 2015 and 2020. Revenue for patent holders continues to decline. Sales are expected to diminish further as TAF and integrase inhibitors dominate regimens.

Long-term Outlook (2025 and beyond)

Abacavir and lamivudine will maintain relevance in LMICs due to affordability. New formulations, such as fixed-dose combinations with TAF, could salvage some revenue. However, innovation in the class is limited, and newer drugs' safety and efficacy profiles will influence adoption.

Pricing Trends

Year	Approximate Price Reduction	Source of Cost Savings
2015	50-70%	Introduction of generics
2020	70-80%	Consolidation of manufacturing and procurement tiers
2025	Stable or declining at low levels	Competitive pressure from newer therapies

Investment Considerations

Pharmaceutical companies need to evaluate whether continuing R&D investments into older NRTIs is viable. As patent expirations approach and market share shrinks, firms may shift focus to next-generation therapies.

---

Key Takeaways

• Market size remains significant in LMICs due to cost and established infrastructure, but demand in high-income countries declines with the uptake of TAF and integrase inhibitors.
• Revenue has sharply declined for patent holders over recent years, with generics dominating sales in resource-limited areas.
• Pricing trends favor low-cost generics, with reductions driven by market competition.
• Clinical guideline shifts toward newer regimens influence future demand.
• Long-term sustainability for older NRTIs depends on regional policies, patent status, and the development of improved formulations.

---

FAQs

1. How does the patent status impact market dynamics for abacavir sulfate and lamivudine?
Off-patent status in most jurisdictions allows generic manufacturers to produce and sell these drugs at lower prices, increasing access but reducing profit margins for original patent holders. Patent expiration drives market erosion in developed countries and boosts generics’ market share globally.

2. Are there emerging alternatives that threaten the market position of these drugs?
Yes. TAF-based regimens, especially combined with integrase inhibitors like dolutegravir, are replacing older NRTIs. These newer drugs have better safety profiles and simplified dosing.

3. What factors influence the affordability of these drugs in resource-limited settings?
Generic competition, international procurement programs, and negotiated discounts significantly lower prices. WHO procurement policies also impact affordability.

4. Can abacavir sulfate and lamivudine still generate substantial revenue in the future?
In high-income markets, revenue diminishes; in LMICs, they remain essential for cost-effective ART. Future revenues depend on the development of fixed-dose combinations and regional health policies.

5. How do regulatory updates and safety concerns influence the market?
Safety concerns relating to abacavir’s hypersensitivity reactions and mitochondrial toxicity of lamivudine influence guideline recommendations. Such shifts can accelerate market decline or adjustment toward newer formulations.

---

References

[1] World Health Organization. "HIV/AIDS Fact Sheet," 2022.
[2] Gilead Sciences Annual Reports, 2014-2022.
[3] WHO Consolidated guidelines on HIV prevention, testing, treatment, service delivery, 2021.